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Abstract
Background: Atherosclerosis is considered the major cause of the dramatic increase in cardiovascular mortality
among patients suffering from chronic kidney disease (CKD). Although the close connection between
atherosclerosis and kidney dysfunction is undeniable, factors enhancing CKD-mediated plaque formation are still
not well recognized.
Results: To increase our knowledge of this process we carried out a comparative proteomic analysis of blood
plasma proteins isolated from 75 patients in various stages of renal dysfunction (CKD group), 25 patients with
advanced cardiovascular disease (CVD group) and 25 healthy volunteers (HV group). The collected samples were
subjected to 2D electrophoresis. Then, individual proteins were identified by mass spectrometry. The comparative
analysis involving CKD and HV groups showed a differential accumulation of a-1-microglobulin, apolipoprotein
A-IV, g-fibrinogen and haptoglobin in patients with kidney disease. Exactly the same proteins were identified as
differentially expressed when proteomes of CVD patients and HV were compared. However, a direct comparison of
CKD and CVD groups revealed significant differences in the accumulation of two proteins: a-1-microglobulin and
apolipoprotein A-IV.
Conclusions: The obtained results indicate that at least two processes differentially contribute to the plaque
formation in CKD- and CVD-mediated atherosclerosis. It seems that the inflammatory process is more intense in
CKD patients. On the other hand, the down- and up-regulation of apolipoprotein A-IV in CVD and CKD groups,
respectively, suggests that substantial differences exist in the efficacy of cholesterol transport in both groups of
patients.
Background
Atherosclerosis, characterized by the accumulation of
lipids, inflammatory cells, and connective tissue within
the intima-media layer of the arterial wall [1], is a well
documented syndrome associated with cardiovascular
disease (CVD). During the last decades the wide spec-
trum of factors that support the development of athero-
sclerotic CVD has been determined. This long list
includes: age, sex, lipid disturbances, hypoalbuminemia,
hyperuricemia, anemia, hyperhomocysteinemia, coagula-
tion anomalies, insulin resistance. Atherosclerosis has
also been recognized as one of the most serious and
frequent complications occurring in patients suffering
f r o mc h r o n i ck i d n e yd i s e a s e(CKD). Interestingly, CVD
risk factors mentioned above seem to be less essential
or even unessential for the emergence of CKD-related
atherosclerosis (CKDA).
The formation of atherosclerotic plaques is considered
the major cause of the dramatic increase in cardiovascular
mortality among CKD patients. Recently, it has been
shown that atherosclerosis can accompany even the early
stages of CKD. This means that the plaque appears long
before the end-stage renal disease (ESRD) is developed [2].
A number of studies suggest that both the acceleration of
atherosclerosis and the increase of the cardiovascular
event risk correlate with the reduction of glomerular filtra-
tion rate (GFR) [3-5]. Compared to the general population,
patients with CKD have a 20-fold higher prevalence of
premature arterial atherosclerosis [6].
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guish at least two types of atherosclerosis: the “classic”
type associated with CVD and the “non-classic” type
associated with CKD. They can produce similar clinical
symptoms, but the mechanisms which underlie the for-
mation of CVD- and CKD-related plaques are not
necessarily identical. The composition of atherosclerotic
lesions in CKD patients and CVD patients with no renal
function impairment is different. Histological studies
demonstrated that atherosclerotic plaques collected
from the CKD patients contain more calcium deposits
within their intimal part but the content of collagenous
fibers and smooth muscle cells is reduced [6,7]. It seems
that the atherosclerotic plaque that forms during
c h r o n i ck i d n e yd i s e a s ei n c l u d e sm o r ei n o r g a n i cs u b -
stances. However, the question of whether the higher
plaque instability observed in CKD patients results from
extended calcification remains open [8].
Recently, a number of uremia-associated factors
enhancing the progression of atherosclerosis were iden-
tified [9]. Some of them are also encountered in the
general population, but others appear to be more spe-
cially linked to CKD: uremic toxins, hypervolemia,
chronic microinflammation, oxidative stress, endothelial
dysfunction, intravenous iron therapy and disturbances
of the calcium-phosphate metabolism.
Although the close connection between atherosclerosis
and kidney dysfunction is undeniable, mechanisms that
enhance the formation of plaque in CKD patients are
still unclear. To increase our knowledge of this phenom-
enon we carried out a standard comparative proteomic
analysis of blood plasma proteins isolated from three
groups of subjects: CKD patients, CVD patients and
healthy volunteers. As a result we identified four pro-
teins whose accumulation changes during CKD develop-
ment. In addition, we found that two of them
accumulate differently in CKD and CVD patients.
Methods
Subjects and samples
This study involved 125 persons divided into five equal
groups. The majority of them were patients with CKD
(75 persons; 21 females, 54 males), treated in the Depart-
ment of Nephrology, Transplantology and Internal Medi-
cine, at Poznan University of Medical Sciences. Based on
The National Kidney Foundation Kidney Disease Out-
comes Quality Initiative guidelines [10] the examined
CKD patients were divided into three groups according
to their eGFR, calculated by the MDRD formula [11].
The first group, CKD1-2, included patients in the initial
stages of CKD (stages 1
st and 2
nd of CKD, with eGFR =
90-60 ml/min/1.73m
2). The second group, CKD3-4,
included pre-dialyzed patients (stages 3
rd and 4
th of CKD,
with eGFR = 59-15 ml/min/1.73m
2). The third group,
CKD5, comprised patients with ESRD (stage 5
th of CKD
with eGFR <15 ml/min/1.73m
2) hemodialyzed for 39.6 ±
9.5 months (mean ± SD) with prescriptions of 4.5-5.5 h/
session, 3 times per week. The fourth group (called CVD)
included 25 patients with CVD with a history and symp-
toms of cardiovascular disease and cardiovascular
instability. No subjects from this group had any clinical
symptoms of renal dysfunction. The fifth, control group
(HV) contained 25 healthy volunteers matched with the
studied groups for age, gender, race, physical activity,
tobacco use and BMI, with normal renal function, with a
negative history of acute or chronic inflammation and
without any clinical symptoms of atherosclerosis. Persons
with diabetes mellitus, an acute inflammatory process
and malignant tumors were excluded from the study.
Demographic data and clinical characteristics of the stu-
died population (n = 125) is shown in Table 1.
The study protocol conforms to the ethical guidelines
of the World Medical Association Declaration of Hel-
sinki. Before the commencement of the project, an
appropriate approval from the Bioethical Commission of
Karol Marcinkowski University of Medical Sciences was
obtained. All participating individuals (i.e. CKD-patients,
CVD patients and healthy volunteers) provided signed
informed consent for treatment and/or study. For all
CKD and CVD patients blood samples were collected
when standard monitoring blood tests were performed.
In the case of hemodialized patients, blood samples
were always drawn before the second hemodialyzis ses-
sion of the week.
Peripheral blood was collected into a closed monov-
ette system containing EDTA and centrifuged immedi-
ately at 1000 g for 15 min. The obtained supernatants
were then centrifuged at 16 000 g for 15 min at 4°C and
frozen at -80°C. Plasma samples were resuspended in
IEF buffer (7 M urea, 2 M thiourea, 2% CHAPS 55 mM
DTT and 0,5% v/v IPG buffer). Insoluble material was
removed by centrifugation at 16 000 g for 20 min. Pro-
tein concentration was estimated using a commercial
2-D Quant kit (GE Healthcare).
2-D electrophoresis
24 cm IPG strips (pH 4-7, GE Healthcare) were actively
rehydrated overnight in IEF buffer contained plasma sam-
ples. Each strip was loaded with the same amount of pro-
tein (1 mg). The strips were subjected to IEF on IPGphor
III (GE Healthcare) using a ramping voltage (50-8000 V)
to final 75 000 Vh. After IEF, IPG strips were incubated
for 15 min in an equilibration buffer (6 M urea, 2% w/v
SDS, 30% v/v glycerol, 50 mM Tris/HCl pH 8.8) with 1%
w/v DTT during the first equilibration step or with 2.5%
iodoacetamide w/v during the second equilibration step.
Second dimension was performed in 11% polyacrylamide
gels using the Ettan DALT six system (GE Healthcare)
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ple, a 2D analysis was repeated three times. After electro-
phoresis, gels were stained with Blue Silver overnight [12]
and scanned (with Umax scanner, GE Healthcare) using
LabScan program.
The images were analyzed using the Image Master Plati-
num software version 6.0 (GE Healthcare). Spots were
detected automatically without filtering. Gel patterns were
automatically matched together between classes. In addi-
tion, all individual matched spots were validated manually
to ensure the correctness of spot matching. To find differ-
ently expressed proteins, gap and ratio measures were
taken into account. For the ratio, a threshold greater than
1.4 was selected. The relative abundance of each spot (%
vol) was calculated as its volume divided by the total
volume of matched spots. Spots showing greatest varia-
tions were subjected to a Shapiro-Wilk normality test to
check the normal distribution of the analyzed population.
Analysis of variance between all classes was performed
using the ANOVA test to check significant differences
between the % volume of each spot in all classes. Unpaired
Student’s t-test was performed to compare between two
particular classes. P values <0.05 were considered statisti-
cally significant. All statistical analyses were performed
using Statistica ver. 8.0 software.
Mass spectrometry (MS)
Protein spots were manually excised from gels, trans-
ferred to Eppendorf tubes and digested with trypsin.
T h ep r o t e i n sw e r ei d e n t i f ied using MALDI-TOF mass
spectrometers. The acquisition of MALDI spectra was
p e r f o r m e do na nA u t o f l e xM A L D I - T O F( B r u k e rD a l -
tonics, Germany) mass spectrometer operated in reflec-
tor mode and using delayed ion extraction. Positively
charged ions in the m/z range 820-3500 were analyzed.
0.5 μl of the sample was co-crystallized with CHCA
matrix and spotted directly on MALDI AnchorChip
target (Bruker Daltonics). For data validation, external
calibration was performed with a standard mixture of
peptides. Flex control v 2.0 was used for the acquisition
of spectra and all further data processing was carried
out using Flex analysis v 2.0. Monoisotopic peptide
masses were assigned and used for databases research.
T h ep r o t e i n sw e r ei d e n t i f i e db yp e p t i d em a s sf i n g e r -
printing using the Mascot (Matrix Science, London, UK)
program against MSDB/Swiss-Prot database. The pro-
tein search was done using the following search para-
meters: mass tolerance +/-0.2 Da, one allowed missed
cleavage, cysteine treated with iodoacetamide to form
carbamidomethyl-cysteine and methionine in the
oxidized form.
Western blot analysis
Western blot analyses were performed according to a
standard procedure. Plasma samples were mixed with
SB buffer (125mM Tris-HCl pH 6.8, 4% SDS, 20% gly-
cerol, 10% 2-mercaptoethanol) and total protein concen-
tration was estimated using a commercial 2-D Quant kit
Table 1 Demographic data and clinical characteristics of the study population (n = 125)
CKD1-2 CKD 3-4 CKD5 CVD HV
age [years] 60.1 ± 8.01 59.9 ± 8.4 60.1 ± 10.1 59.4 ± 9.08 59.5 ± 11.2
males/females 7/18 7/18 7/18 7/18 7/18
body mass index [kg/m2] 28.19 ± 3.05 26.3 ± 2.01 24.7 ± 3.7 28.3 ± 3 24.6 ± 2.1
eGFR [ml/min/1.73m
2] 77.04 ± 22.9 20 ± 7.9 5.75 ± 7 92.7 ± 21.1 123.6 ± 17.6
arterial hypertension 25 (100%) 25 (100%) 25 (100%) 25 (100%) 0 (0%)
history of myocardial infarction/stroke 4 (16%) 5 (20%) 14 (56%) 17 (68%) 0 (0%)
statin treatment 15 (60%) 12 (48%) 17 (68%) 23 (92%) 0 (0%)
IACE treatment 21 (84%) 12 (48%) 15 (60%) 19 (76%) 0 (0%)
total cholesterol [mg/dL] 217.06 ± 52.89 182.33 ± 29.69 179.53 ± 48.39 191.64 ± 41.22 188.73 ± 33.04
HDL cholesterol [mg/dL] 56.2 ± 11.79 58.4 ± 7.64 46.89 ± 23.076 43.62 ± 10.16 70.62 ± 6.32
LDL cholesterol [mg/dL] 168.66 ± 53.11 120.06 ± 17.11 105.97 ± 40.75 118.02 ± 31.66 93.96 ± 30.21
triglycerides [mg/dL] 171.15 ± 70.1 116.66 ± 24.74 133.35 ± 50.83 149.96 ± 75.76 120.72 ± 37.11
alanine aminotransferase (ALT) [IU/L] 22.51 ± 12.52 16.75 ± 9.96 16.01 ± 7.81 23.39 ± 18.9 15.23 ± 6.37
aspartate aminotransferase (AST) [IU/L] 19.72 ± 14.11 16.35 ± 8.54 15.29 ± 5.61 18.8 ± 9.73 16.05 ± 7.56
bilirubin [mg/dL] 0.59 ± 0.82 0.76 ± 0.17 0.53 ± 0.22 0.49 ± 0.18 0.67 ± 0.154
glucose [mg/dL] 93.47 ± 9.52 91.85 ± 9.17 86.01 ± 10.51 92.28 ± 9.96 82.23 ± 12.19
high sensitivity C-reactive protein (hsCRP) [mg/L] 0.62 ± 0.36 6.58 ± 4.05 12.32 ± 18.86 5.96 ± 2.68 1.29 ± 1.39
carotid artery intima media thickness (CA-IMT) [mm] 0.72 ± 0.16 0.74 ± 0.11 0.77 ± 0.32 0.74 ± 0.19 0.48 ± 0.20
No (%) or mean value ± SD.
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were separated by electrophoresis in a 4-12% SDS-polya-
crylamide gel (Bis-Tris NuPAGE, Invitrogen). The sepa-
rated proteins were transferred to a PVDF membrane
and blocked with PBST (PBS plus 0.1% Tween-20) con-
taining 4% BSA. Blots were then incubated overnight
with one of the following primary antibodies (all from
Santa Cruz Biotechnology): anti-a-1-m (a-1-Microglo-
bulin (10A12) antibody, mouse monoclonal), anti-
apoA-IV (apoA-IV (H-240) antibody, rabbit polyclonal),
anti-Hp a (haptoglobin a (B-2) antibody, mouse mono-
clonal), anti-Hp b (haptoglobin b (H-80) antibody, rab-
bit polyclonal), anti-Fb a (fibrinogen a (26E7) antibody,
mouse monoclonal), anti-Fb b (fibrinogen b (H-270)
antibody, rabbit polyclonal), anti-Fb g (fibrinogen g (H-
194) antibody, rabbit polyclonal). Incubation mixtures
contained also anti- a1-antitrypsin antibody (AAT (H-
203) rabbit polyclonal antibody) or anti-C9 antibody (C9
(X197), mouse monoclonal antibody) which were used
as positive controls. After overnight incubation with pri-
mary antibodies, blots were washed and probed with
anti-rabbit or anti-mouse IgG secondary antibodies con-
jugated with Alexa Fluor 633 or 635 (Invitrogen). The
images were captured using Fuji FLA-5100 scanner.
Semi-quantitative analyses of protein accumulation were
carried out with the Image Gauge software version 4.0.
Results
Earlier it had been demonstrated that the development
of atherosclerotic CVD is usually accompanied by sig-
nificant changes in the accumulation of several plasma
proteins [13,14]. Based on this observation we
attempted to determine whether similar changes occur
during the development of kidney dysfunction-related
atherosclerosis. The first question we tried to answer
was whether and how the progression of CKD influ-
ences the composition of blood plasma proteins. For
this purpose plasma samples collected from three
groups of CKD patients: CKD1-2 group (25 patients in
the initial stage of CKD), CKD3-4 group (25 pre-dia-
lyzed patients) and CKD5 group (25 hemodialyzed
patients with ESRD) and from 25 healthy volunteers
(HV group) were subjected to 2D electrophoresis.
After electrophoresis proteins were visualized,
extracted from the gel and examined by mass spectro-
metry. As a result, 42 proteins were identified out of
160 spots observed in an average gel (see Figure 1 and
additional file 1). For all identified proteins the relative
levels of their accumulation in each sample were deter-
mined (mean from three analyses). Finally, comparative
analyses of blood plasma proteomes derived from three
groups of CKD patients (CKD1-2, CKD3-4 and CKD5
proteomes) and healthy volunteers (HV proteome)
were carried out.
Proteomes representing the three groups of patients
were compared among each other and with the HV
proteome. The undertaken analysis revealed that the
following four proteins accumulated in the examined
samples, at different levels: a-1-microglobulin (a-1-m),
apolipoprotein A-IV (apo-A-IV), g-fibrinogen (Fb), and
b-haptoglobin (Hp) (Table 2). For all of them statisti-
cally significant differences were observed if any of the
CKD groups was compared with the HV group. How-
ever, these differences were not always statistically
significant when proteomes of CKD patients were con-
fronted with each other (for details see additional file 2).
Two out of four identified proteins, i.e.: a-1-m and
apo-A-IV occurred only in a single form. The remaining
t w o :F ba n dH po c c u r r e di nt w oa n di nf i v ei s o f o r m s ,
respectively. The results of 2D electrophoresis suggested
that the corresponding isoforms have different isoelec-
tric points (Figure 1). The relative abundance of all four
proteins was higher in each group of CKD patients than
i nt h eH Vg r o u p .H o w e v e r ,o n l yf o ra-1-m was a linear
correlation between protein concentration and CKD
progression observed (Figure 2 and 3a, additional file 3).
For apo-A-IV, we found a significant increase of protein
accumulation during the initial phase of the disease (in
groups CKD1-2 and CKD3-4). Afterwards, it remained
at a similarly high level in group CKD5 (Figure 3b). The
accumulation of Fb and Hp was increased to the similar
levels in all three groups of CKD patients. It is worth
mentioning, however, that the concentration of both
proteins was usually slightly higher in CKD3-4 than in
groups CKD1-2 and CKD5 (Figure 3c,3d). In addition,
we found that the concentration of one Fb isoform (FbI)
and two Hp isoforms (HpI and HpV) grew more rapidly
than the concentrations of corresponding isoforms,
especially in groups CKD1-2 and CKD3-4.
Our second question concerned differences between
blood plasma proteome in CKD and CVD patients.
Because all individuals included to the CVD group dis-
played the symptoms of the advanced cardiac disease we
compared them with the CKD5 group (ESRD patients
have much the same symptoms of cardiac disease as
patients from group CVD) and with healthy volunteers
(group HV was used as a reference). The comparison
between CVD and HV groups showed that exactly the
same set of proteins (a-1-m, apo-A-IV, Fb and Hp) was
differently expressed as earlier when CKD and HV
groups were analyzed (Figure 4, additional file 4). Sur-
prisingly, we found that only two proteins, a-1-m and
apoA-IV, showed significantly different accumulation in
CVD and CKD5 groups. Interestingly, both belong to
the set of four proteins differentially accumulating in all
three CKD and HV groups and in CVD and HV groups.
a-1-m accumulated to higher levels in CVD and CKD5
groups than in the HV group (Figure 4a). However, the
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Page 4 of 12increase of protein concentration was significantly
higher in the blood plasma of CKD5 patients. A differ-
ent pattern of changes was observed for apo-A-IV. In
comparison to HV, its concentration was increased in
the CKD5 group and decreased in the CVD group
(Fig.4b). We observed similar profiles of the accumula-
tion of the two remaining previously identified proteins,
Fb and Hp, in CVD and CKD5 group (Figure 4c, 4d).
For verification of our 2DE-MS results, we performed
western blot analyses of all four differentially accumulat-
ing proteins (a-1-m, apo-A-IV, Fb, and Hp). The ana-
lyses included also a-, b-fibrinogen and a-haptoglobin
chains which were not found using 2DE-MS method.
Western blotting was carried out both for selected indi-
vidual samples and for pooled samples within each
examined group. Based on our 2DE results we decided
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Figure 1 A representative example of the 2D PAGE analysis of plasma samples collected from CKD patients. The presented sample was
obtained from CKD3-4 patient. IEF was performed in pH 4-7. The proteins identified by mass spectrometry are indexed by numbers (see
additional file 1). Differently expressed proteins are boxed.
Table 2 Short characteristic of the proteins differentially expressed in HV and CKD groups as well as in HV and CVD
groups
Spot no. Protein
identification
Accession number
(MSDB)
Sequence coverage
(%)
Queries
matched
Score
(MALDI)
Mol. mass
(kDa)
pI
3 a-1-microglobulin HCHU 29 8 92 39,8 5,95
6 apolipoprotein A-IV LPHUA4 52 21 243 45,3 5,23
18,18a fibrinogen g-B chain FGHUGB 39 15 174 52,1 5,37
2,2a,2b,2c,2d haptoglobin HPHU2 33 12 155 45,8 6,13
The spots corresponding to these proteins showed at least a 1.4-fold increase or reduction of % of volume.
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The representative blots obtained for the pooled
samples are shown in Figure 5. Results of their semi-
quantitative analysis were consistent with those obtained
using a 2DE-MS method. In addition, the data collected
revealed that haptogobin a and fibrinogen b accumu-
lated to similar levels in all studied groups. We found
some fluctuation in fibrinogen a concentration. How-
ever, the differences observed were statistically
insignificant.
Because not all patients included to this study were trea-
ted with statin or IACE (inhibitor of angiotensin-converting
enzyme) we attempted to determine whether the applied
therapy affected the accumulation of differentially
expressed proteins (a-1-m, apo-A-IV, Fb or Hp). To this
end, each examined group of patients (CKD1-2, CKD3-4,
CKD5 and CVD) was divided into two subgroups: treated
and not treated with statin/IACE. Then for each differen-
tially expressed protein, its accumulation levels in both
subgroups were compared. Statistical analysis did not show
any significant differences between protein concentrations
in corresponding subgroups. P values established individu-
ally for each protein in all studied groups of patients
were always much higher than 0.05 (see additional file 5).
HV CKD1-2
CKD3-4 CKD5
CVD
Figure 2 The close-up sections of a-1-m spots visualized by the 2D PAGE analysis of samples isolated from representative patients
belonging to all five examined groups.
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ment influenced the concentrations of a-1-m, apo-A-IV,
Fb, and Hp in patients’ blood plasma.
At present, eGFR is widely used as one of key para-
meters characterizing the level of renal dysfunction.
According to current standards eGFR above 90 ml/min/
1.73m
2 is considered a norm. The results presented above
suggested that the advancement of kidney disease may
also be estimated based on a-1-m protein accumulation in
blood plasma. Indeed, we found a correlation between the
decrease of eGRF and the increase of a-1-m concentration
expressed in %vol (Figure 6). Based on this observation
one could expect that a-1-m protein can serve as an early
indicator of the impairment of kidney functions.
Because patients suffering from a cardiac disease are
at an increased risk of CKD development we attempted
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Page 7 of 12to determine whether the first clinical symptoms of
renal dysfunction are preceded by the increase of a-1-m
a c c u m u l a t i o n .T ot h i se n d ,w ed i v i d e dC V Dp a t i e n t s
into two subgroups. The first one, CVD > 90 included
individuals with normal eGFR, i.e. 90 ml/min/1.73m
2 or
higher. The second one, CVD < 90 included individuals
with eGFR below 90 ml/min/1.73m
2 (mean eGFR in
CVD group was 92.6 ml/min/1.73m
2). Subsequently, we
compared a-1-m accumulation in both subgroups and
in HV and CKD1-2 group (Figure 7). This revealed that
a-1-m occurred at the lowest level in the HV group: the
eGFR mean value was 124 ml/min/1.73m
2.I ng r o u p
CVD > 90 (mean eGFR 106.7 ml/min/1.73m
2) a-1-m
concentration was markedly increased. Such significant
increases of a-1-m accumulation were also observed in
CVD < 90 and CKD1-2 groups. The mean eGFR calcu-
lated for patients classified in these groups was 78.58
and 77.04 ml/min/1.73m
2, respectively.
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The lack of correlation between the well-established risk
factors enhancing atherosclerotic CVD and the emer-
gence of CKD-related atherosclerosis [9] clearly indi-
cates that different mechanisms are involved in plaque
formation in both diseases. However, the question of
how and to what extent these mechanisms differ still
remains open. A comparative analysis of blood plasma
proteomes isolated from patients in different stages of
CKD permitted us to identify four differently expressed
proteins: a- 1 - m ,a p o A - I V ,F ba n dH p .T h ec o l l e c t e d
data also suggest that the first two identified proteins i.
e.: a-1-m and apoA-IV may find practical application as
early markers of nephropathy.
In general, these results seem consistent with observa-
tions made by other authors during their studies invol-
ving only CKD patients. They have earlier found
increased levels of a-1-m in plasma and urine of CKD
patients [15-17] and postulated an inverse correlation
between eGFR and a-1-m concentration in patients
with various renal diseases [18]. There are also a few
reports demonstrating the increased levels of apoA-IV
in hemodialyzed patients [19,20] and in patients in
milder stages of CKD [21]. As a result, a direct correla-
tion between apoA-IV level and CKD progression has
already been suggested [22,23].
Elevated concentrations of Hp and Fb proteins in
CKD patients’ blood or urine have also been reported
earlier although little is known about the role of these
proteins in CKD development. Both of them are positive
acute-phase proteins. Thus, their levels can be increased
during inflammation or infection. The increased accu-
mulation of Hp was observed in the urine of patients
with nephropathy [24]. The elevated level of Fb was
found in the serum of subjects with renal insufficiency
[25,26].
Here, we also provide a first direct comparison of
blood plasma proteomes isolated from CKD and CVD
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Page 9 of 12patients. It demonstrated that the same four proteins (a-
1-m, apoA-IV, Fb and Hp) are differently expressed in
both groups of subjects (CVD and CKD patients). This
would suggest that the differences between mechanisms
mediating plaque formation in CVD and CKD are not
as significant as we expected. This hypothesis is cast
doubt on, however, by the above presented results of
our comparative proteomic analysis of CVD and CKD5
patients with similarly advanced symptoms of athero-
sclerosis. It revealed that two proteins, namely, Hp and
Fb are similarly expressed in both groups of patients.
However, the levels of a-1-m and apoA-IV accumula-
tion are significantly different. This result indicates that
there are some common elements but also some distinct
ones in mechanisms of CVD- and CKD-mediated
atherosclerosis.
It seems that Fb and Hp proteins play the same role
in both diseases. Fb’s primary role is to mediate fibrin
clot formation and platelet aggregation by binding to
cell surface receptors, growth factors, and coagulation
factors [27]. In addition, it was shown that Fb binding
to thrombin and factor XIII produces clots that are
mechanically stiffer and resistant to fibrinolysis [28].
These interactions may explain the association between
Fb levels and atherosclerosis. However, they can also
contribute to pathophysiological processes including
inflammation and thrombosis. The major biological
function of Hp is hemoglobinb i n d i n g .I tp r e v e n t s
hemoglobin-mediated renal parenchymal injury and loss
of iron following intravascular hemolysis [29]. In addi-
tion, haptoglobin can inhibit prostaglandin synthesis and
is believed to have anti-inflammatory and antioxidant
properties [30]. Thus, higher Hp expression can be most
likely classified as a patient’s response to atherosclero-
sis-related stress.
a-1-m is up-regulated in both CVD and CKD patients
but its level is more than 3 times higher in the latter
group. This may indicate that a-1-m plays the same role
in CVD- and CKD-related atherosclerosis although its
contribution to both mechanisms is different. Despite
extensive studies the function and physiological role of
a-1-m protein remain unclear. a-1-m, a member of the
lipocalin superfamily, is a low molecular weight protein
component of plasma first discovered in pathological
human urine [31]. There are several lines of evidence
that a-1-m contributes to the regulation of the immune
system [reviewed in 32]. Accordingly one can speculate
that immunological response is more activated in CKD
patients than in CVD patients.
Our most striking finding concerned the apoA-IV
expression in CKD and CVD groups. It was up-regu-
lated in subjects with chronic kidney dysfunction and
down-regulated in subjects with cardiac disease. ApoA-
IV belongs to a wide group of apolipoproteins which
participate in lipid transport and metabolism. There are
several reports showing that apoA-IV participates in the
reverse cholesterol transport pathway [33,34]. It removes
cholesterol from peripheral cells and transports it to the
liver or to steroidogenic organs where cholesterol is
metabolized. Thus one can hypothesize that insufficient
synthesis of apoA-IV is one of the important factors
affecting atherosclerosis development in CVD patients.
On the other hand, in CKD patients reverse cholesterol
transport should theoretically be increased due to more
effective apoA-IV gene expression. However, the fast
progress of atherosclerosis indicates either that other
components of this pathway do not function properly or
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Page 10 of 12that the production of cholesterol is so high that it can-
not be efficiently removed from blood. The data pre-
sented here are consistent with earlier observations
made by Kronenberg and coworkers. Kronenberg et al.
found that low apoA-IV levels are associated with CVD,
and this association is independent of triglicerides and
HDL cholesterol concentrations. Accordingly, they con-
cluded that apoA-IV may play an antiatherogenic role
[35]. Afterwards, the same authors reported elevated
concentration of plasma apoA-IV in patients with mild
and moderate renal failure [21].
We also found that patient treatment with statin or
IACE does not influence the levels of all four differen-
tially expressed proteins accumulation in blood plasma.
Moreover, the undertaken comparative proteomic analy-
sis revealed that a-1-m can be used not only as a mar-
ker of nephropathy in CKD patients as was postulated
earlier [36,37], but also as a predictive marker for select-
ing among CVD patients with normal eGFR (>90 ml/
min/1.73m
2) those who are in danger of renal failure.
Conclusions
In general, we have found that the same four proteins
differentially accumulate in blood plasma of CKD and
CVD patients. Accumulation of these proteins is not
affected by treatment with statin or IACE. In case of
two proteins: Fb and Hp, the character of the observed
changes was similar in both analyzed groups (CKD5 and
CVD). However, the remaining two proteins a-1-m and
apoA-IV were expressed to significantly different levels.
Thus, our results provide an additional line of evidence
that different molecular mechanisms are involved in the
development of CKD- and CVD-related atherosclerosis.
It seems that the former is highly accelerated by the
inflammatory processes and to a lesser degree affected
by defects in cholesterol transport or metabolism. In
addition, we showed that a-1-m protein can serve as an
early biomarker enabling the prediction of oncoming
renal dysfunction in CVD patients.
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